Triple‐Negative Breast Cancer (TNBC) is an aggressive breast cancer subtype, in which targeting the Trophoblast cell‐surface antigen‐2 (Trop‐2), using antibody‐drug conjugates (ADC), results in significant clinical improvement. Here, TACSTD2 is linked to breast cancer.